Citius Oncology earnings release, August 14, 2026

Citius Oncology, Inc. (CTOR) · Form 8-K, Item 2.02 · Filed · SEC filing

Citius

Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progresses

Strong institutional demand drives growth in total vials ordered and number of institutions ordering

LYMPHIR ordered by 44 institutions since launch

CRANFORD,

N.J., August 14, 2026

/PRNewswire/ -- Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq:

CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”)

(Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.

“Institutional demand (LYMPHIR vials ordered by prescribing centers from wholesalers) is accelerating. Institutional vial orders grew 31% sequentially, from 708 in the quarter ended March 31, 2026 to 926 in the quarter ended June 30, 2026. In July, institutions ordered 383 vials from wholesalers, the largest order month to date, reflecting a 25% increase over the prior quarter’s monthly average order. Currently,

44 institutions have prescribed and ordered LYMPHIR,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology.

“We expect continued institutional demand to drive new wholesaler orders. The Company recognizes revenue when wholesaler orders are fulfilled.

Consequently, net revenue for any period reflects actual wholesaler orders fulfilled. In July, we began to see growth in institutional demand translate into increased wholesale orders and associated revenue. The positive trajectory of formulary approvals, institutional adoption, and unit demand gives us confidence in a robust remainder of the fiscal year,” added Mazur.

“We generated initial momentum with a lean internal team, maintaining healthy product margins and securing broad market access. In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage. The teams are now positioned to accelerate commercial execution and support broader adoption by leveraging the comprehensive, scalable infrastructure already established for LYMPHIR, including patient hub services, marketing and reimbursement support. Citius Oncology is now well positioned to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end and first-in-class support for health care providers. At the same time, we continue to advance LYMPHIR’s longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL,” added Mazur.

“Overall, the launch is moving in the right direction: more institutions are ordering LYMPHIR, vial demand is increasing, and our commercial footprint is expanding. We believe the underlying increasing demand trends provide a strong basis for the remainder of fiscal 2026,” concluded

Mazur.

Fiscal

Third Quarter 2026 Business Highlights and Subsequent Developments²

Fiscal

Third Quarter 2026 Financial Highlights and Subsequent Developments

About

LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl has demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025.

About

Citius Oncology, Inc.

Citius

Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius

Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.³

About

Citius Pharmaceuticals, Inc.

Citius

Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Forward-Looking... (ents

Financial statements

Income Statement

Three Months Ended — FOR THE THREE AND Nine months Ended June 30, 2026 and 2025 (Unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Nine Months Ended – June 30, – 2026Nine Months Ended – June 30, – 2025
Revenues1,493,788$—7,105,197$—
Cost of revenues-491,843-1,609,929
Gross Profit1,001,9455,495,268
Operating ExpensesResearch and development218,496938,2772,316,2025,342,198
Operating ExpensesAmortization of in-process research and development1,720,3124,014,062
Operating ExpensesGeneral and administrative4,219,1631,881,44730,704,1417,446,753
Operating ExpensesStock-based compensation – general and administrative3,560,7912,125,23711,043,5516,022,287
Operating ExpensesTotal Operating Expenses9,718,7624,944,96148,077,95618,811,238
Operating ExpensesOperating Loss-8,716,817-4,944,961-42,582,688-18,811,238
Other Income (Expense)Interest income96,848168,857
Other Income (Expense)Gain on sale of New Jersey net operating losses1,762,000
Other Income (Expense)Amortization of deferred financing costs-179,492-179,492
Other Income (Expense)Interest expense-231,732-160,755-310,604-160,755
Other Income (Expense)Total Other Income (Expense), Net-314,376-160,7551,440,761-160,755
Other Income (Expense)Loss before Income Taxes-9,031,193-5,105,716-41,141,927-18,971,993
Other Income (Expense)Income tax expense (benefit)-107,347264,240-74,317792,720
Other Income (Expense)Net Loss-8,923,846-5,369,956-41,067,610-19,764,713
Other Income (Expense)Net Loss Per Share - Basic and Diluted-0.08-0.08-0.42-0.28
Weighted Average Common Shares OutstandingBasic and diluted (includes pre-funded warrants from the December 2025 offering)107,890,45271,552,40298,413,98971,552,402

Balance Sheet

June 30, 2026 — (Unaudited)

June 30, 2026September 30, 2025
Current Assets:Cash and cash equivalents16,563,7053,924,908
Current Assets:Accounts receivable, net of allowances686,235
Current Assets:Inventory22,625,94522,286,693
Current Assets:Prepaid expenses2,831,2801,331,280
Current Assets:Total Current Assets42,707,16527,542,881
Other Assets:In-process research and development, net of accumulated amortization69,385,93873,400,000
Other Assets:Total Assets112,093,103100,942,881
Current Liabilities:Accounts payable7,315,51613,234,684
Current Liabilities:License payable15,650,00022,650,000
Current Liabilities:Accrued expenses25,836,1204,093,124
Current Liabilities:Due to related party9,985,5589,513,771
Current Liabilities:Total Current Liabilities58,787,19449,491,579
Current Liabilities:Notes payable, net of deferred financing costs6,410,161
Current Liabilities:Deferred tax liability2,710,6432,784,960
Current Liabilities:Note payable to related party3,800,1113,800,111
Current Liabilities:Total Liabilities71,708,10956,076,650
Stockholders’ Equity:Common stock - $0.0001 par value; 400,000,000 shares authorized at June 30, 2026 and September 30, 2025; 105,758,982 and 83,513,442 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively10,5768,351
Stockholders’ Equity:Additional paid-in capital145,481,984108,897,836
Stockholders’ Equity:Accumulated deficit-105,107,566-64,039,956
Stockholders’ Equity:Total Stockholders’ Equity40,384,99444,866,231
Stockholders’ Equity:Total Liabilities and Stockholders’ Equity112,093,103100,942,881

Cash Flow

(Unaudited)

20262025
Cash Flows From Operating Activities:Net loss-41,067,610-19,764,713
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense11,043,5516,022,287
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of in-process research and development4,014,062
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of deferred financing costs179,492
Adjustments to reconcile net loss to net cash used in operating activities:Deferred income tax expense-74,317792,720
Changes in operating assets and liabilities:Accounts receivable, net of allowances-686,235
Changes in operating assets and liabilities:Inventory-339,252-8,940,201
Changes in operating assets and liabilities:Prepaid expenses-1,500,0001,600,000
Changes in operating assets and liabilities:Accounts payable-5,919,1684,955,797
Changes in operating assets and liabilities:Accrued expenses19,980,4968,458,554
Changes in operating assets and liabilities:Due to related party471,7876,875,556
Changes in operating assets and liabilities:Net Cash (Used In) Provided By Operating Activities-13,897,194
Cash Flows From Investing ActivitiesLicense payments-7,000,000
Cash Flows From Investing ActivitiesNet Cash Used In Investing Activities-7,000,000
Cash Flows From Financing ActivitiesNet proceeds from notes payable9,635,000
Cash Flows From Financing ActivitiesNet proceeds from exercise of warrants and pre-funded warrants9,730,818
Cash Flows From Financing ActivitiesDeferred Financing Costs-892,551
Cash Flows From Financing ActivitiesNet proceeds from issuance of common stock15,062,724
Cash Flows From Financing ActivitiesNet Cash Provided by Financing Activities33,535,991
Cash Flows From Financing ActivitiesNet Change in Cash and Cash Equivalents12,638,797
Cash Flows From Financing ActivitiesCash and Cash Equivalents – Beginning of Period3,924,908112
Full release

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as “will,” “anticipate,”

“estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq’s continued listing standards; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain, perform under, and maintain third party agreements and relationships, including obtaining a new bulk drug substance supplier; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; risks relating to the results of research and development activities; our ability to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings, which are available on the SEC’s website at www.sec.gov, including in

Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

Contacts

Investor

Contact:

Ilanit Allen ir@citiuspharma.com

908-967-6677 x113

Media

Contact:

STiR-communications

Greg Salsburg greg@stir-communications.com – Financial Tables Follow –⁴

CITIUS

ONCOLOGY, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Citius Oncology earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.